1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

06 May 2024
Admin
News Article

Angle Signs Commercial Agreement with Large Pharma

Angle signs commercial agreement with Large Pharma to develop Parsortix-based androgen receptor

Overview

Angle plc, a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announced that it has signed a supplier agreement with Large Pharma to develop a Parsortix-based androgen receptor (AR) detection assay for use in prostate cancer studies.

Terms of Agreement

Under the terms of this agreement, worth £550,000 to Angle, the company will develop a CTC-based AR assay.
Assay development will take place in the Angle's UK laboratories, with project completion expected in Q1 2025.
A successful development phase will demonstrate the importance of the Parsortix system in assessing the efficacy of prostate cancer therapeutics and offers the potential for long-term, ongoing business for the company supporting clinical studies.

Androgen Receptor

Androgen receptor is a nuclear protein involved in cell growth and proliferation, cell cycle progression, protein synthesis, and cell death.
The analysis of Parsortix harvested CTCs using the company's AR assay could enable longitudinal, minimally invasive assessment of AR status throughout clinical studies and during follow-up.

Comments from Angle

• CEO

CEO of Angle, Andrew Newland commented: ""This is further validation of Angle's Parsortix system which shows potential for long-term large-scale revenues in bringing innovative new cancer drugs to the market. We anticipate that success in this first phase of assay development may lead to much larger contracts for use of the assay in clinical trials.""

• CSO

Angle’s chief scientific officer, Karen Miller commented: ""We are delighted our expertise is being put to use in the isolation, harvest, and profiling of CTCs for androgen receptor investigation with the potential for Angle's assays to be used in clinical trials. The new androgen receptor assay will also be an important addition to the menu of assays we can offer other customers.""

Prostate Cancer

Prostate cancer is the second most common cancer in men with 1.5 million new cases diagnosed globally each year and 5 million men living with prostate cancer (5-year prevalence).
The androgen receptor plays a pivotal role in prostate cancer tumour growth and progression with anti-androgen therapy frequently given as first-line treatment.
However, response is variable, and 20-30% of patients go on to develop resistance, resulting in disease progression and the development of metastatic castration resistant prostate cancer (mCRPC), which is currently incurable.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!